Skip to Main Content

Author Details

Christopher R Cogle
College of Medicine, University of Florida
2003
141
36
PMIDPaper TitleJournal TitlePublished Year
37647621Prevalence of Underreported Nicotine Exposure Among US Nonsmoking Adults: A Comparison of Self-Reported Exposure and Serum Cotinine Levels From NHANES 2013-2020.Nicotine Tob Res2024
36111891Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML.Blood Adv2023
37086851Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care.Transplant Cell Ther2023
37078412Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.Cancer2023
36655622Home Modifications for Older Adults: A Systematic Review.J Appl Gerontol2023
36652143Targeting Redundant ROBO1 and SDF-1 Pathways Prevents Adult Hemangioblast Derived-EPC and CEC Activity Effectively Blocking Tumor Neovascularization.Stem Cell Rev Rep2023
36804046Comparative effectiveness of mobile health smoking cessation approaches among underserved patients in primary care: Study protocol for the PROMOTE-UP trial.Contemp Clin Trials2023
34728061Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR] Trial).Am J Cardiol2022
36374488Medicaid's Moment for Protecting and Promoting Women's Health.JAMA2022
35868306Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell2022
35096610<i>Post-hoc</i> Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA.Front Oncol2022
35180428HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia.Mol Cell2022
35206878Impact of the COVID-19 Pandemic on Colorectal and Prostate Cancer Screening in a Large U.S. Health System.Healthcare (Basel)2022
34990262Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.J Clin Oncol2022
33356566Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.Future Oncol2021
33808758Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar.Healthcare (Basel)2021
33499867Building a precision oncology workforce by multidisciplinary and case-based learning.BMC Med Educ2021
33800077Implementation of Cancer Plans in the United States: A Review.Healthcare (Basel)2021
34439266A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.Cancers (Basel)2021
34771451Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436.Cancers (Basel)2021
33945316Following the Breadcrumbs of Palliative Care Financial Sustainability to Big Data.J Palliat Med2021
33222075Finding incident cancer cases through outpatient oncology clinic claims data and integration into a state cancer registry.Cancer Causes Control2021
33220019Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.Int J Lab Hematol2021
31629722Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients.Hematol Oncol Stem Cell Ther2020
35847712Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect<sup>®</sup> MDS/AML Disease Registry.EJHaem2020
33321907Functional Dependency Analysis Identifies Potential Druggable Targets in Acute Myeloid Leukemia.Cancers (Basel)2020
32708922Cancer in the Time of Coronavirus: A Call for Crisis Oncology Standards of Care.Healthcare (Basel)2020
32702549Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes.Leuk Res2020
32670283Identification of Unique mRNA and miRNA Expression Patterns in Bone Marrow Hematopoietic Stem and Progenitor Cells After Trauma in Older Adults.Front Immunol2020
32407443Clinical Application of Computational Methods in Precision Oncology: A Review.JAMA Oncol2020
32236943Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.Br J Haematol2020
32402250RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia.Cell Stem Cell2020
32397113Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.Int J Mol Sci2020
30641417Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics.Leuk Res2019
31786140HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice.Cancer Cell2019
31888052A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia.Cancers (Basel)2019
31299413Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia.Leuk Res2019
31208955A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.Blood Adv2019
31009835Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.Leuk Res2019
30917515Continuous Rural-Urban Coding for Cancer Disparity Studies: Is It Appropriate for Statistical Analysis?Int J Environ Res Public Health2019
30852241Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.Clin Lymphoma Myeloma Leuk2019
31050908Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise.J Clin Oncol2019
30642575Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.Leuk Res2019
28556233Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.J Clin Apher2018
29995404Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells.J Med Chem2018
29800400Using social media to assess care coordination goals and plans for leukemia patients and survivors.Transl Behav Med2018
30114559CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.Leuk Res2018
30401521CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation.Leuk Res2018
30333627Functional genomic landscape of acute myeloid leukaemia.Nature2018
29769208Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation.Clin Cancer Res2018
  • 1 - 50 of 141

Recommended Authors

Yale Cancer Center and Yale School of Medicine
Career Start Year 2018
Number of shared co-authors 1
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 3
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 3
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 14
NYU Robert I. Grossman School of Medicine
Career Start Year 2006
Number of shared co-authors 3
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 26
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 4
Graduate School of Medicine, The University of Tokyo
Career Start Year 2004
Number of shared co-authors 0
Universite Paris Cite, INSERM, CNRS
Career Start Year 2004
Number of shared co-authors 3
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 4
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 2
Hopp Children's Cancer Center (KiTZ)
Career Start Year 2000
Number of shared co-authors 6
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 14
Smilow Cancer Center, Yale University School of Medicine
Career Start Year 1997
Number of shared co-authors 5
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 30
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 14
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 11
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 24
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 6
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 9
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 31
Fred Hutchinson Cancer Center
Career Start Year 1989
Number of shared co-authors 26
Queens University Belfast Belfast
Career Start Year 1988
Number of shared co-authors 1
Sidney Kimmel Cancer Center, Johns Hopkins University
Career Start Year 1986
Number of shared co-authors 4
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 40
Oregon Health & Science University
Career Start Year 1983
Number of shared co-authors 21
Memorial Sloan-Kettering Cancer Center
Career Start Year 1982
Number of shared co-authors 22
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 1978
Number of shared co-authors 0
Washington University School of Medicine
Career Start Year 1978
Number of shared co-authors 7

Collaborators

College of Medicine, University of Florida
Co-authored papers 14
The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital
Co-authored papers 13
MD Anderson Cancer Center
Co-authored papers 9
University of Miami, Sylvester Comprehensive Cancer Center
Co-authored papers 7
University of Kansas Medical Center
Co-authored papers 7
University of Colorado Division of Hematology
Co-authored papers 7
Cellworks Group Inc.
Co-authored papers 6
Co-authored papers 5
Cellworks Group Inc.
Co-authored papers 5
The University of Texas Southwestern Medical Center
Co-authored papers 4
Oregon Health & Science University School of Medicine
Co-authored papers 4
Co-authored papers 4
Novartis Institutes for BioMedical Research
Co-authored papers 4
College of Medicine, University of Florida
Co-authored papers 4
Moffitt Cancer Center
Co-authored papers 4
Co-authored papers 4
Oregon Health and Science University
Co-authored papers 4
Oregon Health & Science University
Co-authored papers 4
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
University of Texas Southwestern Medical Center
Co-authored papers 3
Co-authored papers 3
Oregon Health & Science University, University of California Berkeley
Co-authored papers 3
Harvard Medical School
Co-authored papers 3
St. Jude Children's Research Hospital.
Co-authored papers 3
The Ohio State University
Co-authored papers 3
Pyeongtak University
Co-authored papers 3